Clinical Trial: A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Alpha 1-Antitrypsin Deficiency
Study Type: INTERVENTIONAL
Official Title: A Phase 1 Study of Inhaled KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
Brief Summary:
The Sponsor is developing KB408, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human SERPINA1 to the airways of people with alpha-1 antitrypsin deficiency (AATD) via nebulization.This study is designed to evaluate safety and pharmacodynamics of KB408 in adults with AATD with a PI*ZZ genotype.Three planned dose levels of KB408 will be evaluated in single dose escalation cohorts.Subjects taking intravenous AAT augmentation…
Read more